Diestelhorst M, Aspacher F, Konen W, Krieglstein G K, Hilgers R D
Universitäts-Augenklinik, Köln, Federal Republic of Germany.
Graefes Arch Clin Exp Ophthalmol. 1992;230(5):451-3. doi: 10.1007/BF00175932.
Using non-invasive anterior chamber fluorophotometry, we performed a double-blind, randomized clinical trial on the effects of dexamethasone 0.1% and prednisolone acetate 1.0% eye drops on the blood-aqueous barrier after phacoemulsification and posterior chamber lens implantation. Twenty patients received one of the preparations topically to the surgically treated eye 5 times daily for a period of 5 days, beginning the day after surgery. Patients chosen for the study had no history of eye disease other than senile cataract nor of systemic diseases influencing the eyes. No other steroids or non-steroidal anti-inflammatory drugs were given before or during the investigation. The fluorometric data measured 5 days after surgery show a lower mean concentration of fluorescein in the dexamethasone alcohol 0.1% treated group compared with the prednisolone acetate 1.0% treated group. The difference is statistically not significant. The clinical assessment of postoperative ocular inflammation did correlate with the fluorophotometric measurements. The results of the study indicate that although dexamethasone is the more potent anti-inflammatory agent, with a better binding affinity to glucocorticoid receptors, we are--with the number of cases measured--unable to demonstrate any difference in the efficacy in protecting the blood-aqueous barrier after cataract extraction and posterior chamber lens implantation to prednisolone acetate.
我们使用非侵入性前房荧光光度法，针对0.1%地塞米松滴眼液和1.0%醋酸泼尼松龙滴眼液对白内障超声乳化吸除及后房型人工晶状体植入术后血-房水屏障的影响，进行了一项双盲随机临床试验。20例患者在手术后次日开始，每天5次将其中一种制剂局部应用于手术治疗眼，持续5天。入选该研究的患者除老年性白内障外无眼部疾病史，也无影响眼部的全身性疾病史。在研究前及研究期间未给予其他类固醇或非甾体类抗炎药。术后5天测得的荧光光度数据显示，0.1%地塞米松醇治疗组的荧光素平均浓度低于1.0%醋酸泼尼松龙治疗组。差异无统计学意义。术后眼部炎症的临床评估与荧光光度测量结果相关。研究结果表明，尽管地塞米松是更强效的抗炎药，对糖皮质激素受体的结合亲和力更好，但就我们所测量的病例数而言，在白内障摘除及后房型人工晶状体植入术后保护血-房水屏障的疗效方面，我们无法证明其与醋酸泼尼松龙有任何差异。
